TEK and ovarian carcinoma: TIE2 has been shown to be predictive of a response to anti-angiogenic agents in biliary and colorectal cancer [23] and is currently being evaluated in the frontline setting in ovarian cancer in the VALTIVE 1 trial (NCT 04523116).